InflammX Therapeutics
PrivateLast Round
Series A
Jan 10, 2025
Total Funding Raised
$67.95M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InflammX Therapeutics is a clinical-stage biopharmaceutical company developing Xiflam, an orally administered small molecule to treat retinal diseases such as the dry form of age-related macular degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InflammX Therapeutics Comparables
Compare InflammX Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Belite Bio, Inc | 73% | |
| Alkeus Pharmaceuticals | 71% | |
| Kodiak Sciences Inc. | 67% | |
InflammX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 10, 2025 | ||||
| Series B | Jul 24, 2012 | ||||
| Series A | Sep 25, 2008 |
InflammX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RusnanoMedInvest | Series B |
| Domain Associates | Series B, Series A |
| GBS Venture Partners | Series B, Series A |
| BioPacificVentures | Series A, Series B |
| ExSight Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Monthly visitors increased 375% MoM to 1.3K.
- Feb 1, 2026
Monthly visitors increased 175% MoM.
InflammX Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about InflammX Therapeutics's valuation, stock price, and market status.